ReviewNature reviews. Rheumatology2010
The safety profile of biologic therapies for juvenile idiopathic arthritis.
Review in Nature reviews. Rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 78 citations in OpenAlex.
- A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system.Archives of dermatological research · 2025Article
- Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?Clinical rheumatology · 2024Article
- Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.Pediatric rheumatology online journal · 2022Article
- Juvenile idiopathic arthritis.Nature reviews. Disease primers · 2022Review
- Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.Rheumatology international · 2021Article
- Tapering of Biological Agents in Juvenile ERA Patients in Daily Clinical Practice.Frontiers in medicine · 2021Article
- Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee.Arthritis research & therapy · 2020Observational
- Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.Blood advances · 2018Article
- Education and employment in patients with juvenile idiopathic arthritis - a standardized comparison to the German general population.Pediatric rheumatology online journal · 2017Article
- Infection-Related Death among Persons with Refractory Juvenile Idiopathic Arthritis.Emerging infectious diseases · 2016Article
- Association between drug intake and incidence of malignancies in patients with Juvenile Idiopathic Arthritis: a nested case-control study.Pediatric rheumatology online journal · 2016Article
- DNA methylation at IL32 in juvenile idiopathic arthritis.Scientific reports · 2015Article
- The development and assessment of biological treatments for children.British journal of clinical pharmacology · 2015Review
- A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.Clinical rheumatology · 2015Article
- Advances from clinical trials in juvenile idiopathic arthritis.Nature reviews. Rheumatology · 2013Review
- Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.Paediatric drugs · 2013Article
- Premature cell senescence and T cell receptor-independent activation of CD8+ T cells in juvenile idiopathic arthritis.Arthritis and rheumatism · 2013Article
- A series of patients on anti-TNF therapy referred to a multidisciplinary lung cancer service.Irish journal of medical science · 2013Article
- What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Arthritis research & therapy · 2013Review
- Genome-scale case-control analysis of CD4+ T-cell DNA methylation in juvenile idiopathic arthritis reveals potential targets involved in disease.Clinical epigenetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of juvenile idiopathic arthritis (JIA) has been revolutionized by the use of novel biologic agents that have much improved patients' short-term and, according to early evidence, long-term outcomes. Currently available biologic agents used to treat patients with JIA include tumor necrosis factor (TNF) blockers, various agents that target interleukin (IL)-1 and the IL-6 receptor, T-cell co-stimulation inhibitors and antibodies to B-lymphocyte antigen CD20. These agents are increasingly used early in the course of the disease (often in combination with other immunosuppressive medications) and often for long periods of time, as patients can be difficult to wean from their use. Safety concerns (especially the long-term effects of biologic therapy) are, therefore, being examined more closely. For instance, in 2009, the FDA issued a warning related to the development of malignancies in patients with JIA who had used anti-TNF medications for >2.5 years. In this Review, data related to the safety profile of all currently available biologic agents used to treat JIA are examined, with a particular focus on anti-TNF therapy, the most studied biologic agent for JIA. Safety issues that need further study, including the implementation of registries to monitor long-term drug safety, are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.